Research Progress on the Basis and Clinical Applications of Peiyuan Anti-Cancer Decoction in the Treatment of Oncological Diseases

Authors

  • Yuanyue Zhang Shaanxi University of Chinese Medicine, Xianyang, China Author
  • Hailong Si The First Clinical Medical College of Shaanxi University of Chinese Medicine, Xianyang, China Author

DOI:

https://doi.org/10.70088/2sr4h907

Keywords:

peiyuan anti-cancer decoction, integrative oncology, tumor microenvironment, chemotherapy, traditional chinese medicine

Abstract

Malignant tumors represent a major global public health challenge, characterized by persistently high incidence and mortality rates that demand innovative therapeutic strategies. Peiyuan Anti-Cancer Decoction, a representative traditional Chinese medicine (TCM) formula in integrative oncology, has attracted considerable attention in both basic experimental research and clinical practice in recent years. Grounded in the TCM principle of strengthening the body's vital qi while eliminating pathogenic factors, this formula exerts anti-tumor effects through multi-target, multi-pathway synergistic mechanisms. These include modulation of immune function, regulation of tumor cell signaling pathways, enhancement of radiotherapy and chemotherapy efficacy with concurrent toxicity reduction, and improvement of patients' clinical symptoms and overall quality of life. Accumulating clinical evidence indicates that Peiyuan Anti-Cancer Decoction can augment the therapeutic effectiveness of conventional radiotherapy and chemotherapy, alleviate treatment-related adverse effects, and, to a certain extent, prolong survival in the comprehensive management of malignant tumors such as lung cancer and primary liver cancer. Its core therapeutic value lies in integrating the strengths of both medical systems by combining the Western medicine paradigm of direct tumor targeting with the TCM strategy of regulating the internal physiological environment, thereby establishing an integrated treatment model that harmonizes offensive and defensive therapeutic approaches. This paradigm aligns with the contemporary shift in oncology from single-target confrontation toward holistic balance. This article systematically reviews the mechanisms of action, clinical efficacy, and current research status of Peiyuan Anti-Cancer Decoction, and discusses future development directions, aiming to provide a valuable reference for optimizing integrative oncology treatment strategies.

References

D. Xia, W. Li, C. Tang, and J. Jiang, "Astragaloside IV, as a potential anticancer agent," Frontiers in Pharmacology, vol. 14, p. 1065505, 2023.

M. Zhong, Y. Li, H. Wang, N. Fan, X. Chu, L. Liu, and H. Fu, "Integrated network pharmacology and experimental validation reveal EGFR/p53/Bcl-2–mediated anti-hepatocellular carcinoma effects of Zedoary Turmeric Oil," Journal of Ethnopharmacology, vol. 352, p. 120241, 2025.

H. Zhang, X. Yue, Z. Chen, C. Liu, W. Wu, N. Zhang, and G. Liu, "Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials," Molecular Cancer, vol. 22, no. 1, p. 159, 2023.

S. Zucker, J. Cao, and W. T. Chen, "Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment," Oncogene, vol. 19, no. 56, pp. 6642–6650, 2000.

A. Albini, D. Trapani, F. Bertolini, D. M. Noonan, R. Orecchia, and G. Corso, "From combination early detection to multicancer testing: shifting cancer care toward proactive prevention and interception," Cancer Prevention Research, vol. 18, no. 10, pp. 583–602, 2025.

D. Wu, R. Zhou, H. Chen, Y. Pan, Y. Tang, and D. Zhou, "The role of traditional Chinese medicine in the management of cervical cancer," The American Journal of Chinese Medicine, vol. 52, no. 04, pp. 1013–1025, 2024.

H. B. Yu, J. Q. Hu, B. J. Han, Y. Y. Du, S. T. Chen, X. Chen, and H. G. Zheng, "Combinatorial treatment with traditional medicinal preparations and VEGFR-tyrosine kinase inhibitors for middle-advanced primary liver cancer: A systematic review and meta-analysis," PLOS ONE, vol. 19, no. 11, p. e0313443, 2024.

B. Pei, Z. A. Wen, Y. Zheng, and X. Li, "Network Pharmacology-Based Approach to Investigate the Mechanisms of Piwei-Peiyuan Decoction in the Treatment of Gastric Carcinoma," 2021.

H. Yan, Y. Li, B. Guo, B. Yang, and D. Tang, "The effect of Traditional Chinese Medicine on patients undergoing targeted therapy for primary liver cancer: a systematic review and meta-analysis," Frontiers in Oncology, vol. 15, p. 1674965, 2025.

J. Zhang, Y. Wu, Y. Tian, H. Xu, Z. X. Lin, and Y. F. Xian, "Chinese herbal medicine for the treatment of intestinal cancer: preclinical studies and potential clinical applications," Molecular Cancer, vol. 23, no. 1, p. 217, 2024.

P. Wu, J. J. Dugoua, O. Eyawo, and E. J. Mills, "Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis," Journal of Experimental & Clinical Cancer Research, vol. 28, no. 1, p. 112, 2009.

J. Dai, H. Shui, Y. Wu, H. Zhang, Y. Li, S. Zhang, and D. Tang, "Effects of Jianpi therapy for cancer-related fatigue: a meta-analysis of randomized controlled trials," Frontiers in Oncology, vol. 15, p. 1512460, 2025.

M. B. Meng, Y. L. Cui, Y. S. Guan, Z. Ying, M. H. Zheng, C. K. Yuan, and R. M. Zhang, "Traditional Chinese medicine plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma," The Journal of Alternative and Complementary Medicine, vol. 14, no. 8, pp. 1027–1042, 2008.

Y. Jiang, F. F. Liu, Y. Q. Cai, P. Zhang, X. F. Yang, X. Y. Bi, and L. S. Liu, "Oral decoctions based on Qi-Yin syndrome differentiation after adjuvant chemotherapy in resected stage ΙΙΙA Non-Small cell lung cancer: A randomized controlled trial," Integrative Cancer Therapies, vol. 23, p. 15347354241268271, 2024.

J. Huang, J. X. Li, L. R. Ma, D. H. Xu, P. Wang, L. Q. Li, and P. Y. Yan, "Traditional herbal medicine: a potential therapeutic approach for adjuvant treatment of non-small cell lung cancer in the future," Integrative Cancer Therapies, vol. 21, p. 15347354221144312, 2022.

J. Y. Lee, E. H. Kim, J. H. Yoon, W. Eo, and S. W. Yoon, "Traditional herbal medicine, Sipjeondaebo-Tang, for cancer-related fatigue: a randomized, placebo-controlled, preliminary study," Integrative Cancer Therapies, vol. 20, p. 15347354211040830, 2021.

Downloads

Published

08 August 2026

Issue

Vol. 3 No. 3 (2026)

Section

Article

License

Copyright (c) 2026 Yuanyue Zhang, Hailong Si (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Zhang, Y. and Si, H. (2026) “Research Progress on the Basis and Clinical Applications of Peiyuan Anti-Cancer Decoction in the Treatment of Oncological Diseases”, Medicine Insights, 3(3), pp. 89–98. doi:10.70088/2sr4h907.